Preview

Атеротромбоз

Расширенный поиск

КЛИНИЧЕСКИЙ РАЗБОР ПАЦИЕНТА С РЕЦИДИВИРУЮЩИМИ ВЕНОЗНЫМИ ТРОМБОЭМБОЛИЧЕСКИМИ ОСЛОЖНЕНИЯМИ

https://doi.org/10.21518/2307-1109-2017-2-79-94

Полный текст:

Аннотация

Представлен клинический разбор больного с рецидивирующими венозными тромбоэмболическими осложнениями. Даны рекомендации по современным принципам диагностики, выбора лечебной тактики у больных с данной патологией. Большое внимание уделено вопросам антикоагулянтного лечения, неадекватность или отказ от которого приводит к развитию тяжелых, трудноустранимых последствий.

Об авторе

А. Л. КОМАРОВ
Институт клинической кардиологии им. А.Л. Мясникова НМИЦ кардиологии Минздрава России
Россия
д.м.н.


Список литературы

1. VTE Impact Assessment Group in Europe. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost, 2007, 98: 756–764.

2. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost, 2014 Aug, 112(2): 255-63. Martinez C, Cohen AT, Bamber L, Rietbrock S.

3. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal. doi: 10.1093/eurheartj/ehu283.

4. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. Chest, 2016, 149(2): 315-352.

5. Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. A Scientific Statement From the American Heart Association. Circulation, 2011, 123: 1788-1830.

6. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология, 2015, 4(выпуск 2).

7. Pollack CV, Schreiber D, Goldhaber SZ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol, 2011 Feb 8, 57(6): 700-6.

8. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2)(Suppl): e419S–e494S

9. Schulman S, Kakkar A, Goldhaber S et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation,2014, 129: 764-772.

10. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. The EINSTEIN–PE Investigators. N Engl J Med, 2012, 366: 1287-97.

11. Kimmel SE, French B, Kasner SE et al. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med, 2013, 369: 2283-93.

12. Limone BL, Hernandez AV, Michalak D, Bookhart BK, Coleman CI. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. Thromb Res., 2013 Oct, 132(4): 420-6.

13. Воробьева Н.М., Панченко Е.П., Добровольский А.Б., Титаева Е.В., Ермолина О.В., Балахонова Т.В., Кириенко А.И. Улучшение реканализации глубоких вен и «исходы» венозных тромбоэмболических осложнений при продленной терапии эноксапарином. Ангиология и сосудистая хирургия, 2011, 17(1): 87-96.

14. Воробьева Н.М., Панченко Е.П., Кириенко А.И., Добровольский А.Б., Титаева Е.В., Ермолина О.В., Балахонова Т.В., Андрияшкин В.В., Леонтьев С.Г. Варварин или эноксапарин: что назначить больному венозным тромбозом в первый месяц лечения? Терапевтический архив, 2009, 81(9): 57-61.

15. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. The EINSTEIN–PE Investigators. N Engl J Med, 2012, 366: 1287-97.

16. van Es J, Douma RA, Kamphuisen PW et al. Clot resolution after 3 weeks of anticoagulant treatment for pulmonary embolism: comparison of computed tomography and perfusion scintigraphy. J Thromb Haemost., 2013 Apr, 11(4): 679-85.

17. Oral Rivaroxaban for Symptomatic Venous Thromboembolism The EINSTEIN Investigators. N Engl J Med, 2010, 363: 2499-510.

18. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med, 2001 Jul 19, 345(3): 165-9.

19. Couturaud F, Sanchez O, Pernod G, et al. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. JAMA, 2015 Jul 7, 314(1): 31-40.

20. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. European Genetics foundation, Cardiovascular Disease Educational and Research Trust, International Union of Angiology, Mediterranean League on Thromboembolism. Int Angiol, 2005 Mar, 24(1): 1-26.

21. Ensor J, Riley RD, Moore D, Snell KI, Bayliss S, Fitzmaurice D. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open, 2016 May 6, 6(5): e011190. doi: 10.1136/bmjopen2016-011190.

22. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med, 2013 Feb 21, 368(8): 709-18.

23. Raskob G, Ageno W, Cohen AT, et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol, 2016 May, 3(5): e228-36.

24. Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, Becattini C, Uresandi F, Verhamme P, Monreal M, RIETE investigators. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res, 2015 Apr, 135(4): 666-72.

25. Brighton TA, Eikelboom JW, Mann et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med, 2012, 367: 1979-87.

26. Becattini C, Agnelli G, Schenone A et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med, 2012, 366: 1959-67.

27. Palareti G1, Cosmi B, Legnani C et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med, 2006 Oct 26, 355(17): 1780-9.

28. Palareti G, Cosmi B, Legnani C et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood, 2014 Jul 10, 124(2): 196-203.

29. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet, 1996 Aug 17, 348(9025): 423-8.

30. Морева О.В., Кропачева Е.С., Добровольский А.Б., Титаева Е.В., Панченко Е.П. Факторы риска рецидива кровотечений при терапевтических значениях международного нормализованного отношения у больных, длительно получающих варфарин. Кардиология, 2016, 56(2): 40-46.

31. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of CardiologyWorking Group on Thrombosis European Heart Journal, 2016, 0: 1–11. doi: 10.1093/eurheartj/ehw454.

32. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21, 368(8): 699-708.

33. http://www.acc.org/education-and-meetings/imageand-slide-gallery/mediadetail?id=bc5d26c3e66845ae8b29d1e7159118f9.

34. Weitz JI, Lensing AWA, Prins MH, et al for EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med, 2017 Mar 30, 376(13): 1211-1222.

35. Marc Carrier, Alejandro Lazo_Langner, Sudeep Shivakumar et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med, 2015, 373: 697-704.

36. Alok A. Khorana, Marc Carrier, David A. Garcia, Y. Lee. Guidance for the prevention and treatment of cancerassociated venous thromboembolism. J Thromb Thrombolysis, 2016, 41: 81–91.

37. Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res, 2014, 134(6): 1214–1219.

38. Watson HG, Keeling DM, Laffan M et al. Guideline on aspects of cancer-related venous thrombosis. British Journal of Haematology, 2015, 170: 640–648.

39. Bayer Pharma AG. Bayer Extends Clinical Investigation of Xarelto® for the Prevention and Treatment of LifeThreatening Blood Clots in Patients with Cancer (Press Release). Available at: https://www.xarelto.com/en/resources/newsfeed/bayer-еxtends-clinical-investigation-of-xarelto-for-the-prevention-and-treatment-of-life-threatening-bloodclots-in-patients-with-cancer/. Accessed May 18, 2016.


Для цитирования:


КОМАРОВ А.Л. КЛИНИЧЕСКИЙ РАЗБОР ПАЦИЕНТА С РЕЦИДИВИРУЮЩИМИ ВЕНОЗНЫМИ ТРОМБОЭМБОЛИЧЕСКИМИ ОСЛОЖНЕНИЯМИ. Атеротромбоз. 2017;(2):79-94. https://doi.org/10.21518/2307-1109-2017-2-79-94

For citation:


KOMAROV A.L. CLINICAL DISCUSSION OF A PATIENT WITH RECURRENT VENOUS THROMBOEMBOLIC COMPLICATIONS. Atherothrombosis Journal. 2017;(2):79-94. (In Russ.) https://doi.org/10.21518/2307-1109-2017-2-79-94

Просмотров: 176


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)